Form 4: Mirum Pharmaceuticals Director Patrick Heron Reports Stock Purchases

Director Patrick Heron reports purchases of Mirum Pharmaceuticals stock through Frazier Life Sciences X, L.P. and Frazier Life Sciences IX, L.P.

Summary

• Patrick Heron, a director of Mirum Pharmaceuticals, reported purchasing shares of common stock through Frazier Life Sciences X, L.P. on March 14, 2025, and March 17, 2025.
• On March 14, 2025, 528 shares were purchased at a weighted average price of $44.1125, with prices ranging from $44.00 to $44.15.
• On March 17, 2025, 21 shares were purchased at a weighted average price of $43.9338, with prices ranging from $43.925 to $43.945.
• Following these transactions, the total shares held by Frazier Life Sciences X, L.P. is 168,672.
• Additionally, 3,566,912 shares are held by Frazier Life Sciences IX, L.P.
• Heron disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock purchases by a director. The purchases themselves could be interpreted as a slightly positive signal.

Positives

• Director's purchase may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders.

Stakeholder Impact

• Shareholders may view the director's stock purchase as a positive signal.

Key Dates